Home Companies Catalysts Deep Dives
Petosemtamab petosemtamab PHASE3
Drug Profile
ModalityBispecific
RouteIV
Therapy AreaOncology
Peak Sales Est$2000M
Formulations[]
Companies
GMAB (ORIGINATOR)100%
Mechanism: LGR5xEGFR bispecific
Expert: Bispecific antibody targeting LGR5 (cancer stem cell marker) and EGFR for head and neck squamous cell carcinoma.
Everyday: Targets two proteins on cancer cells to block their growth.
Targets: ["LGR5","EGFR"]
Programs (2)
IndicationStageKey StudyRegional Status
1L HNSCCPHASE3PESTO-1L[]
R/R HNSCCPHASE3PESTO-3L[]
Upcoming Catalysts (3)
Petosemtamab - HNSCC - Ph3 - Interim (LiGeR-HN2) H2 2026
Petosemtamab - HNSCC - Ph3 - Interim (LiGeR-HN1) H2 2026
Petosemtamab - HNSCC - BLA Filing H1 2027
Notes
From Merus acquisition ($8B). Dual breakthrough therapy designation. Phase 3 in 1L and 2L+ HNSCC. Data expected 2026, potential launch 2027. First-in-class targeting cancer stem cells via LGR5.
Data from Supabase · Updated 2026-03-24